Anti-amyloid compounds containing benzofurazan
Inventors
Reed, Mark A. • Wood, Thomas K. • Banfield, Scott C. • Barden, Christopher J. • Yadav, Arun • Lu, Erhu • Wu, Fan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
In general, among other things, compounds of Formula I are provided: in which R11 is e.g., 4-(pyrrolidin-1-yl)piperidin-1-yl, N-methyl-3-(pyrrolidin-1-yl)propan-1-amino, N1,N1,N3-trimethylpropane-1,3-diamino, N,N-dimethylpiperidin-4-amino, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethanon)azetidin-1-yl, or 3-(morpholin-1-ylmethyl)azetidin-1-yl; R13 is, e.g., phenyl optionally substituted with one or more substituents; and R12 and R14 are each independently hydrogen or alkyl. Methods of treatment are also provided.
Core Innovation
The invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, in which R11 is selected from specified amine-containing ring substituents and R13 is selected from specified optionally A-substituted heteroaromatic and aromatic groups. R12 and R14 are each independently hydrogen or alkyl.
The disclosed compounds include benzo[c][1,2,5]oxadiazole-based and benzofurazan-based Formula I compounds, with a fused bicyclic heteroaromatic core and an amine-containing side chain. The examples include variations with piperidine, azetidine, pyrrolidine, and morpholine motifs, together with heteroaryl and aryl substitutions.
The invention further defines provisos that restrict certain connections of substituent A. If A is 1-ol-2,2,2-trifluoroethan-1-yl, it cannot be connected to phenyl or thiophene, and if A is methanonyl, it cannot be connected to phenyl.
Claims Coverage
The consolidated claim coverage identifies one independent Formula I genus with four structural variables and two connection provisos. The inventive features center on the allowed R11 and R13 selections, the independent hydrogen or alkyl selection for R12 and R14, and the restrictions on certain A substituent connections.
Formula I compound with defined R11 substituent set
A compound of Formula I, or a pharmaceutically acceptable salt thereof, in which R11 is selected from the specified amine-containing ring substituents, including piperidine-, azetidine-, pyrrolidine-, and morpholine-containing variants.
Formula I compound with defined R13 heteroaryl or aryl set
A compound of Formula I, or a pharmaceutically acceptable salt thereof, in which R13 is selected from oxazole, oxadiazole, phenyl, thiophene, thiazole, furan, pyrazole, N-methylpyrazole, and pyridine, each optionally substituted with one or more substituents A.
R12 and R14 independently hydrogen or alkyl
A compound of Formula I, or a pharmaceutically acceptable salt thereof, in which R12 and R14 are each independently hydrogen or alkyl.
Connection provisos for substituent A
A compound of Formula I, or a pharmaceutically acceptable salt thereof, with provisos that if A is 1-ol-2,2,2-trifluoroethan-1-yl it cannot be connected to phenyl or thiophene, and if A is methanonyl it cannot be connected to phenyl.
Overall, the claim coverage is limited to the Formula I compound genus defined by the specified R11 and R13 substituent sets, the hydrogen or alkyl options for R12 and R14, and the explicit provisos restricting particular A connection patterns.
Stated Advantages
Inhibits amyloid oligomerization and/or amyloid aggregation.
Provides treatment methods and pharmaceutical compositions for amyloidosis and amyloid diseases.
Documented Applications
Treatment of amyloid diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, progressive supranuclear palsy, prion diseases, senile systemic amyloidosis, and Type 2 diabetes mellitus.
Application to CNS and systemic amyloidosis or amyloid diseases.
Interested in licensing this patent?